Evergreen Therapeutics, Inc.

This study tests an experimental pill (EG-301) added to standard AREDS2 supplements in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. The goal is to see if the drug can slow vision loss and reduce damage to the retina over 6 months. Participants…

This study tests whether adding a drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. About 28 adults whose cancer has returned after chemotherapy will take part. The main goal is to chec…

This early-stage study tests a new drug called EG-101 in 24 healthy women to check its safety before giving it to pregnant women with severe pre-eclampsia, a dangerous condition that causes high blood pressure and organ damage. The study measures how the drug moves through the bo…

This phase 3 trial tests whether adding the drug EG007 to a standard two-drug therapy (lenvatinib plus pembrolizumab) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 adults whose cancer has returned after platinum che…